RESEARCH - Programmed release formulation of prednisone safe and effective for RA

[Guest guest]

Horizon Pharma, Inc. Announces Results Of Phase 3 Study Of LODOTRA®

Demonstrate 12-Month Sustained Efficacy And Safety In Rheumatoid

Arthritis

MedicalNewsToday.com

Article Date: 27 Jul 2010 - 1:00 PDT

Horizon Pharma, Inc. announced the results from the extended open

label portion of The Circadian Administration of Prednisone in

Rheumatoid Arthritis-1 (CAPRA-1) Phase 3 European registration study

of LODOTRA®, a programmed release formulation of low-dose prednisone,

which showed sustained improvement in reducing the duration of morning

stiffness in patients with Rheumatoid Arthritis (RA) over a 12 month

period. The results were published in the July issue of the ls of

Rheumatic Diseases and were also recently presented at the European

League Against Rheumatism (EULAR) Annual Congress.

************************************************

Read the full article here:

http://www.medicalnewstoday.com/articles/195896.php

Not an MD